Video

Dr. Carey Discusses the Need for Targeted Therapy in TNBC

Author(s):

Lisa A. Carey, MD

In Partnership With:

Dr. Lisa Carey Discusses the Need for Targeted Therapy in Triple Negative Breast Cancer (TNBC)

Lisa A. Carey, MD, associate professor, Breast Cancer Hematology/Oncology at UNC Lineberger Comprehensive Cancer Center discusses the need for targeted therapy in triple negative breast cancer

Related Videos
Hope S. Rugo, MD
Idoroenyi Amanam, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Srikala Sridhar, MD, MSc, FRCPC
Andrea Wolf, MD, MPH
Suzanne Lentzsch, MD, PhD
Margaret E. Gatti-Mays, MD, MPH, FACP
Domenica Lorusso, MD, PhD
Martin H. Voss, MD
Jacob Sands, MD
Related Content
FDA
October 11th 2024

FDA Approves Single-Dose, Intravenous Paclitaxel Biosimilar for Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Sunil Adige, MD
October 10th 2024

Shining a Light on the Importance of Prevention Strategies During Breast Cancer Awareness Month

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Joseph A. Sparano, MD, of Mount Sinai
October 7th 2024

Next Generation of CDK Inhibitors Are Breaking Ground in HER2– Breast Cancer

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.
October 5th 2024

The OncFive: Top Oncology Articles for the Week of 9/29